Form 4: Ironwood Pharmaceuticals Director Julie McHugh Acquires Shares

Director Julie McHugh acquired 24,311 shares of Ironwood Pharmaceuticals stock on June 18, 2024.

Summary

• On June 18, 2024, Julie McHugh, a director of Ironwood Pharmaceuticals, acquired 24,311 shares of Class A Common Stock.
• The shares were acquired at a price of $0.
• Following the transaction, McHugh directly owns 163,839 shares of Ironwood Pharmaceuticals.
• The restricted stock vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of a director's stock acquisition. While insider buying can be seen as positive, this is a relatively small transaction and doesn't necessarily indicate a strong bullish signal.

Positives

• A director's acquisition of shares can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities, providing investors with insights into the actions of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as insider buying is often viewed favorably.

Key Dates